Oncology Corporate Profile
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|TPIV 110||immunotherapy||Breast Cancer||II|
|TPIV 200||immunotherapy||Platinum-resistant Ovarian cancer||II|
|TPIV 200||immunotherapy||Platinum-sensitive Ovarian cancer||II|
|TPIV 200||immunotherapy||Triple negative Breast cancer||II|
View additional information on product candidates here »
3/24/2017 12:03 pm
[Marketwired] - NetworkNewsWire , a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. , an NNW client focused on leading the field of oncology ...
3/22/2017 03:00 pm
[PR Newswire] - JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...
3/18/2017 05:00 pm
3/14/2017 08:00 pm
[PR Newswire] - TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
3/14/2017 08:00 pm
3/14/2017 01:01 pm
[PR Newswire] - JACKSONVILLE, Fla., March 14, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS). If successful, TapImmune's vaccine may replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women. "This is our second T-cell vaccine candidate to be tested in a DoD-funded Phase 2 study to the Mayo Clinic, and it marks our expansion into a second breast cancer indication," said Dr. Glynn Wilson, chairman and CEO of TapImmune.